Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
Type:
Grant
Filed:
April 26, 2013
Date of Patent:
February 21, 2017
Assignees:
MDC Max-Delbruck-Centrum Fur Molekulare Medizin Berlin-Buch, Fresenius Medical Care Deutschland GmbH
Inventors:
Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube
Abstract: A peptide having an ED50 of less than 500 nm, in particular 10 nM to an antibody which recognizes an epitope on an extracellular ?1 loop 2 or ?2 loop 1 of a human adrenoceptor wherein the antibody's binding to the epitope results in an increase of ?-secretase activity, an increased release of ?-amyolid molecules and/or cellular dysfunction of cerebral blood vessel cells, glia cells or neurons, wherein the ED50 value is measured by bioassay.
Type:
Grant
Filed:
January 15, 2009
Date of Patent:
June 4, 2013
Assignees:
MDC Max-Delbruck-Centrum fur Molekulare Medizin Berlin-Buch, Fresenius Medical Care Deutschland GmbH
Inventors:
Rudolf Kunze, Gerd Wallukat, Peter Rosenthal, Richard Straube